SI-BONE Beats Q2 Revenue, Raises 2026 Outlook on Surging Procedure Volume
SIBN sits 44% above its 52-week low of $11.48.
Summary
SI-BONE delivered Q2 revenue of $56.01M, beating the $55.34M consensus, driven by a 14.9% jump in U.S. procedure volume and 19% growth in active physicians. Adjusted EBITDA swung to a positive $2.8M, a 178% improvement, signaling operating leverage. Management raised the low end of 2026 revenue guidance to $231M-$233M (15-16% growth) and trimmed opex growth guidance to ~12%, implying margin expansion. This follows a strong Q1 beat and reinforces the commercial momentum of the iFuse platform. The stock closed at $17.76 on July 31, well below the $23.50 median analyst target, leaving room for a positive reaction.
At the time of this announcement, SIBN was trading at $16.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $818.2M. The 52-week trading range was $11.48 to $21.89. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.